Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Orphai Therapeutics Inc.
UPDATE – Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
May 18, 2026
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
May 18, 2026
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD
May 18, 2026
Orphai Therapeutics’ Phase 2a LAM-001 Study Selected for Oral Presentation at the American Thoracic Society (ATS) 2026 International Conference
January 20, 2026